Dogwood Therapeutics, Inc (NASDAQ:DWTX) Sees Significant Drop in Short Interest

Dogwood Therapeutics, Inc (NASDAQ:DWTX) was the target of a significant decrease in short interest during the month of January. As of January 30th, there was short interest totaling 63,632 shares, a decrease of 29.8% from the January 15th total of 90,610 shares. Based on an average daily trading volume, of 42,977 shares, the short-interest ratio is presently 1.5 days. Approximately 2.9% of the shares of the company are sold short. Approximately 2.9% of the shares of the company are sold short. Based on an average daily trading volume, of 42,977 shares, the short-interest ratio is presently 1.5 days.

Hedge Funds Weigh In On Dogwood Therapeutics

An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new position in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned approximately 0.51% of Dogwood Therapeutics at the end of the most recent quarter. 9.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently issued reports on DWTX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Dogwood Therapeutics in a report on Monday, December 22nd. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Dogwood Therapeutics in a research note on Friday, January 30th. Finally, Wall Street Zen lowered Dogwood Therapeutics to a “strong sell” rating in a report on Saturday, December 13th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Dogwood Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $12.00.

Dogwood Therapeutics Price Performance

Shares of DWTX stock traded up $0.05 during trading hours on Friday, reaching $3.07. 13,508 shares of the company’s stock were exchanged, compared to its average volume of 37,126. The company’s 50 day moving average is $3.95 and its two-hundred day moving average is $5.00. The company has a market cap of $7.04 million, a P/E ratio of -0.12 and a beta of 1.88. Dogwood Therapeutics has a 1 year low of $2.60 and a 1 year high of $14.69.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.